



10th August, 2022

To,
The Manager - Corporate Relationship Dept.
BSE Limited
P. J. Towers, Dalal Street
Fort, Mumbai - 400 001

To,
The Manager - Corporate Compliance
National Stock Exchange of India Ltd
Exchange Plaza, Plot No.C-1,
G Block,BKC, Bandra (E),
Mumbai 400 051

Scrip Code: BSE - 524500

Scrip Code: NSE - KILITCH

Sub: Outcome of Board Meeting

Dear Sir,

In continuation of our letter dated 2nd August, 2022 and pursuant to Regulation 30 and Regulation 33 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby would like to inform you that the Board of Directors of the Company at its meeting held today i.e. Wednesday, 10th August, 2022 have considered and approved the following;

1. Unaudited Financial Results (Standalone and Consolidated) for the quarter ended 30th June, 2022. The copy of Unaudited Financial Results (Standalone and Consolidated) as considered and approved by the Board of Directors along with Limited Review Report by the Auditors are enclosed herewith for your ready reference.
2. Notice of 30th Annual General Meeting of the Company for the financial year ended 31st March, 2022 to be convened and held on Thursday, 29th September, 2022 at 10:00 am through video conferencing and other audio visual means.
3. Appointment of Mr. Deep Shukla, Practicing Company Secretary as Scrutinizer to conduct the entire voting process at the 30th AGM of the Company (including e-voting) and to submit the Report for declaration of the results thereof.
4. Pursuant to regulation 42 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, the Register of Members and Share Transfer Books of the Company shall remain closed from Thursday, 22nd September, 2022 to Thursday, 29th September, 2022 (both days inclusive) pursuant to regulation 42 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 for the purpose of 30th AGM of the Company.
5. Appointment of M/s Arvind Kumar & Co. Cost Accountants (Firm Registration No.000646) as Cost Auditor of the Company for the financial year 2022-23 subject to

**MUKUND
PRATAPRAI
MEHTA**

Digitally signed by MUKUND PRATAPRAI MEHTA
DN: c=IN, o=PERSONAL, pseudonym=de3699b434193df53a7b94312df7895b18e89a9e2563279b6a31143cf2144ac, postalCode=400037, st=MAHARASHTRA, serialNumber=42eb6afed00f3b1ff1d748907a2c2a1a953655160e7a4314c1dd0ade1d0c2491, cn=MUKUND PRATAPRAI MEHTA
Date: 2022.08.10 18:11:00 +05'30'



ratification of the same by members of the Company at the ensuing General Meeting of the Company, his profile is enclosed herewith.

6. Alteration of Memorandum of Association of the Company due to increase in the Authorised Share Capital of the Company to Rs. 25,00,00,000 divided into 2,50,00,000 equity shares of Rs. 10 each subject to the approval of members of the Company at the ensuing General Meeting of the Company.

The Board Meeting commenced at 16:30 hours and concluded at 18:20 hours.

Request you to kindly take note of the same and acknowledge the receipt.

Thanking you,

Yours Faithfully,

For **Kilitch Drugs (India) Limited**

MUKUND

PRATAPRAI MEHTA

Digitally signed by MUKUND PRATAPRAI MEHTA
DN: c=IN, o=PERSONAL,
pseudonym=de.3699b434193df53a7b943120fa7895b18e8
9a9c25632796a31143c12144ac, postalCode=400037,
st=MAHARASHTRA,
serialNumber=42eb6afe00f3b1ff1d748907a2ca1a95365
516007b4314c1db0ade1d0c2491, cn=MUKUND
PRATAPRAI MEHTA
Date: 2022.08.10 18:10:27 +05'30'

Mukund Mehta
Managing Director



KILITCH DRUGS (INDIA) LIMITED

UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2022

Regd. Office:- C-301/2, MIDC, TTC Industrial Area, Pawane Village, Thane-400701
Tel No: 022- 61214100, Email id: info@kilitch.com, Website: www.kilitch.com
CIN:L24239MH1992PLC066718

(Rs. In Lakhs except Earnings per Share data)

Sr. No.	Particulars	Three Months Ended			Year Ended
		6/30/2022	3/31/2022	6/30/2021	3/31/2022
		Unaudited	Audited (Refer Note 4)	Unaudited	Audited
1	Income				
	Net Sales/ Income from operations	2,356.88	3,203.07	1,951.15	10,515.98
	Other Income	139.21	76.85	148.41	455.90
	Total Income	2,496.09	3,279.92	2,099.56	10,971.88
2	Expenses				
	(a) Cost of Materials Consumed	1,158.87	1,777.46	1,079.08	6,028.55
	(b) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	40.11	(7.75)	13.75	(4.69)
	(c) Employee Benefit Expenses	158.76	162.88	140.10	615.45
	(d) Finance Cost	7.28	17.71	12.75	66.27
	(e) Depreciation and Amortisation Expenses	27.23	25.88	23.30	96.42
	(f) Export Product Registration/Commission	168.29	123.03	147.55	542.79
	(g) Other Expenses	518.08	749.82	327.71	2,234.27
	Total Expenses	2,078.62	2,849.03	1,744.24	9,579.06
3	Profit / (Loss) before Exceptional items (1-2)	417.47	430.89	355.32	1,392.82
4	Exceptional Items	-	-	-	-
5	Profit / (Loss) from ordinary activities before tax (3+4)	417.47	430.89	355.32	1,392.82
6	Less: Tax Expenses:-				
	Current Tax	128.00	143.05	61.45	363.37
	Deferred Tax	(11.98)	(14.48)	5.18	(23.32)
7	Net Profit / (Loss) after Tax for the period from Continuing Operations (5-6)	301.45	302.32	288.69	1,052.77
8	Other Comprehensive Income (after tax)	(220.14)	(37.29)	149.11	198.15
9	Total Comprehensive Income (after taxes) (7+8)	81.31	265.03	437.80	1,250.92
10	Paid-Up equity share capital (Face Value Rs 10 per share)	1,558.23	1,558.23	1,556.20	1,558.23
11	Other Equity				16,244.89
12	Earning per share (not annualised)				
	(a) Basic	1.93	1.94	1.86	6.76
	(b) Diluted	1.93	1.94	1.86	6.76

Notes:

- The above Unaudited Financial Results of the Company for the quarter ended 30th June, 2022 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on 10th August, 2022
- The Statement has been prepared in accordance with companies (Indian Accounting Standards) Rule, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- The Company is predominantly engaged in the business of Pharmaceuticals, whose results are reviewed regularly by chief operating decision maker for making decisions about resource allocation and performance assessment. As such, there are no separate reporting segments as per Ind-AS108.
- The figures for the quarter ended 31st March, 2022 are the balancing figures between the audited figures in respect of full financial year ended 31st March, 2022 and unaudited published year to date figures upto the nine months of the respective financial year.
- Previous period figures have been regrouped and reclassified wherever necessary.

Place : Mumbai
Dated: 10th August 2022



For and on behalf of the Board of Directors

Mukund P. Mehta
Managing Director





Independent Auditor's Review Report on the Quarterly Standalone Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,
The Board of Directors of
Kilitch Drugs (India) Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of **Kilitch Drugs (India) Limited** (the 'Company') for the quarter ended 30th June, 2022, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (the "Listing Regulations").
2. The Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition & measurement principles laid down in the Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules thereafter and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with the recognition and measurement principles laid down in applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For SURYAPRAKASH MAURYA & Co.
Chartered Accountants
Firm Registration No. 147410W


(Suryaprakash Maurya)
Proprietor

Membership No. 178258
UDIN: 22178258AOT0VJ1660



Place : Mumbai

Dated: August 10, 2022

KILITCH DRUGS (INDIA) LIMITED
UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE, 2022

Regd. Office:- C-301/2, MIDC, TTC Industrial Area, Pawane Village, Thane-400701
 Tel No: 022- 61214100, Email id: info@kilitch.com, Website: www.kilitch.com
 CIN:L24239MH1992PLC066718

(Rs. In Lakhs except Earnings per Share data)

		Three Months Ended			Year Ended
		6/30/2022	3/31/2022	6/30/2021	3/31/2022
		Unaudited	Audited (Refer Note 4)	Unaudited	Audited
1	Income				
	Net Sales/Income from Operations	3,345.27	3,660.75	1,962.49	11,423.42
	Other Income	97.14	37.83	105.38	290.93
	Total Income	3,442.41	3,698.58	2,067.87	11,714.35
2	Expenses				
	Cost of Materials Consumed	1,976.15	2,055.88	1,637.94	6,548.03
	Changes in inventories of finished goods, work-in-progress and Stock-in-Trade	40.11	(7.75)	(538.61)	(4.69)
	Employee Benefit Expenses	278.94	163.57	140.99	618.31
	Finance Cost	67.15	71.28	12.75	119.84
	Depreciation and Amortisation Expenses	82.27	112.69	44.41	246.56
	Export Product Registration/Commission	173.16	128.37	147.55	548.13
	Other expenses	534.91	815.98	484.25	2,676.73
	Total Expenses	3,152.69	3,340.02	1,929.28	10,752.91
3	Profit before Exceptional items (1-2)	289.72	358.56	138.59	961.44
4	Exceptional Items	-	-	-	-
5	Profit from ordinary activities before tax (3+4)	289.72	358.56	138.59	961.44
6	Less : Tax Expenses				
	Current Income Tax	128.00	143.05	61.45	363.37
	Deferred Tax	(11.98)	(14.47)	5.18	(23.30)
7	Profit after tax for the period from continuing operations (5-6)	173.70	229.98	71.96	621.37
	Add/(Less): Share in Profits /(Loss) of Associates	-	-	-	-
8	Net Profit/(Loss) After Tax & Share in Profits /(Loss) of Associates	173.70	229.98	71.96	621.37
9	Other Comprehensive Income (after Tax)	(220.14)	(37.29)	149.12	198.15
10	Total Comprehensive Income (after taxes) (8+9)	(46.44)	192.69	221.08	819.52



Handwritten signature

11	Net Profit / (Loss) attributable to				
	a) Owner of the Company	208.62	289.82	118.77	736.73
	b) Non Controlling interest	(34.92)	(59.84)	(46.81)	(115.36)
12	Other Comprehensive Income attributable to				
	a) Owner of the Company	(220.14)	(37.29)	149.12	198.15
	b) Non Controlling interest	-	-	-	-
13	Total Income attributable to				
	a) Owner of the Company	(11.52)	252.53	267.89	934.88
	b) Non Controlling interest	(34.92)	(59.84)	(46.81)	(115.36)
14	Paid-Up equity share capital (Face Value Rs. 10 per share)	1,558.23	1,558.23	1,556.20	1,558.23
15	Other Equity				12,350.41
16	Earning per share (not annualised)				
	(a) Basic	1.34	1.86	0.76	4.73
	(b) Diluted	1.34	1.86	0.76	4.73

Notes:

- The above unaudited Consolidated Financial Results of the Company for the quarter ended 30th June, 2022 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on 10th August, 2022.
- The Statement has been prepared in accordance with companies (Indian Accounting Standards) Rule, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- The Group is predominantly engaged in the business of Pharmaceuticals, whose results are reviewed regularly by chief operating decision maker for making decisions about resource allocation and performance assessment. As such, there are no separate reporting segments as per Ind-AS108.
- The figures for the quarter ended 31st March, 2022 are the balancing figures between the audited figures in respect of full financial year ended 31st March, 2022 and unaudited published year to date figures upto the nine months of the respective financial year.
- Previous period figures have been regrouped and reclassified wherever necessary.

Place: Mumbai
Date: 10th August, 2022



For and on behalf of the Board of Directors

Mukund P. Mehta
Managing Director





Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,

**The Board of Directors of
Kilitch Drugs (India) Limited**

1. We have reviewed the accompanying statement of Unaudited Consolidated Financial Results of **Kilitch Drugs (India) Limited** ("the Parent"), and its' subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter 30th June, 2022, being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This statement which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether Statement is free of material misstatements. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019 issued by the Securities and Exchange Board of India under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, to the extent applicable.

4. The Statement includes the results of entities as given below:

List of Subsidiaries:

1. Monarchy Healthserve Private Limited
 2. Kilitch Estro Biotech PLC – Foreign Subsidiary
5. We did not review the interim financial results and other financial information in respect of one subsidiary whose interim financial results/information reflects, total revenues of Rs. Nil, total net profit/(loss) after tax of Rs. (21.93) Lakhs and total comprehensive income/(loss) of Rs. (21.93) Lakhs for the quarter ended 30th June, 2022. These interim financial results and other financial information have been reviewed by other auditors, whose reports have been furnished to us by the management of the Company and our conclusion in so far as it relates to the affairs of such subsidiary is based solely on the report of other auditors.




6. The Statement includes interim financial results and other financial information in respect of one foreign subsidiary which reflects, total revenues of Rs. 1,011.93 Lakhs, total net profit/(loss) after tax of Rs. (105.82) Lakhs and total comprehensive income/(loss) of Rs. (105.82) Lakhs for the quarter ended 30th June, 2022 as considered in the consolidated financial results. These financial statements have been furnished to us by the management and our opinion on the statement, in so far as it relates to the amounts included in respect of this subsidiary is solely based on such unaudited financial statements as certified by the management. Our conclusion on the Statement is not modified in respect of the above matter.
7. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on management certified financial statements referred in paragraph 6 above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with the relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For SURYAPRAKASH MURYA & Co.

Chartered Accountants

Firm Registration No. 147410W



(Suryaprakash Maurya)

Proprietor

Membership No. 178258

UDIN: 22178258AOTPI08540



Place : Mumbai

Dated: August 10, 2022

Details of Cost Auditor

Firm Name	Arvind Kumar & Co. (Cost Accountants)
Partner Name	Mr. Arvind Kumar
Address	D - 202, 2nd Floor, Vrushali Shilp, Chikuvadi, Road, Borivali (W), Mumbai - 400092
Membership No.	37904
Firm Registration number	000646
Email Id	office.arvindkumarandco@yahoo.com
Experience (In years)	8 years
Area of experience	Accounts, Taxation (including international Taxation), Matters, Internal Audits, Cost Audits
Disclosure of Relationships between Directors in case of appointment	There is no relationship between directors and the cost auditor

